摘要
目的:了解阿司咪唑上市后心脏毒性的类型及发生原因。方法:收集1991～2007年国内公开发表有关阿司咪唑心脏毒性的报道文献30篇,共38例。通过文献计量分析法,对不良反应文献所涉及患者资料、用药方法等进行回顾性分析。结果:阿司咪唑的心脏毒性表现为尖端扭转型室性心动过速、室性心动过速、房室传导阻滞和QT间期延长。其发生原因多与过量有关。结论:阿司咪唑心脏毒性作用绝大多数为A类不良反应,可预知,可预防,通过选择适应证,控制用药剂量可予以预防。
Objective： To study the astemizole safety in the cardiovascular system after its marketing through retrieving a large number of literatures. Method： 30 literatures published during 1991 -2007 about the astemizole safety in the cardiovascular system were collected and reviewed from national medical journals. Result： 38 cases with adverse reactions were reported. The cardiotoxicity of astemizole was associated with torsades de pointes, ventricular arrthythmia, atrioventricular blockage and prolongation of the QT interval, and their occurrences were more concerned with its over-dosage. Conclusion： the astemizole safety in the cardiovascular system was A-ADRs.
出处
《药物流行病学杂志》
CAS
2009年第2期85-87,共3页
Chinese Journal of Pharmacoepidemiology
基金
国家食品药品监督管理局药品评价中心委托项目
关键词
阿司咪唑
心脏毒性
上市后药物安全性监测
Astemizole
Cardiotoxicity
Postmarketing monitoring of drug safety
